E.S. ZAMANOVA², N.G. SHAMSUTDINOVA¹, D.I. ABDULGANIEVA^1, 2

 ¹Kazan State Medical University, Kazan

²Republic Clinical Hospital, Kazan

Contact details:

Zamanova E.S. — rheumatologist

Address: 138 Orenburgsky trakt, Kazan, Russian Federation, 420064, tel.: +7-939-731-19-10, e-mail: endzhe.zamanova@mail.ru

The article presents a description of a clinical case of the course of the new coronavirus infection in a patient with a diffuse form of scleroderma. The debut of the viral infection occurred against the background of a long course of systemic scleroderma, as well as long-term therapy with immunosuppressive drugs. The complexity of diagnosing and managing patients with COVID-19 combined with immunoinflammatory rheumatic diseases is discussed.

Key words: COVID-19, systemic scleroderma, rheumatology.

REFERENCES

1. Nasonov E.L. Coronavirus disease 2019 (COVID-19): reflections of a rheumatologist. Nauchno-prakticheskaya revmatologiya, 2020, no. 58 (2), pp. 123–132 (in Russ.).
2. Kingsmore K.M., Grammer A.C., Lipsky P.E. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol, 2020, vol. 16 (1), pp. 32–52. DOI: 10.1038/s41584-019-0337-0
3. Sarzi-Puttini P., Marotto D., Caporali R. et al. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun, 2021, vol. 116, p. 102545. DOI: 10.1016/j.jaut.2020.102545
4. Emmi G., Bettiol A., Mattioli I. et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev, 2020, vol. 19 (7), pp. 102575. DOI: 10.1016/j.autrev.2020.102575
5. Costantino F., Bahier L., Tarancón L.C. et al. COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Joint Bone Spine, 2020, pp. 105095. DOI: 10.1016/j.jbspin.2020.105095
6. Han H., Yang L., Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med, 2020, vol. 58 (7), pp. 1116–1120. DOI: 10.1515/cclm-2020-0188
7. Nasonov E.L., Beketova T.V., Reshetnyak T.M., Lila A.M., Anan’eva L.P., Lisitsina T.A., Solov’ev S.K. Coronavirus disease 2019 (COVID-19) and immunoinflammatory rheumatic diseases: at the crossroads of thrombo-inflammation and autoimmunity. Nauchno-prakticheskaya revmatologiya, 2020, no. 58 (4), pp. 353–367 (in Russ).
8. Goeijenbier M., van Wissen M., van de Weg C., Jong E., Gerdes V.E. et al. Viral infections and mechanisms of thrombosis and bleeding. J Med Virol, 2012, vol. 84 (10), pp. 1680–1696. DOI: 10.1002/ jmv.23354
9. Jackson S.P., Darbousset R., Schoenwaelder S.M. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood, 2019, vol. 133 (9), pp. 906–918. DOI: 10.1182/blood-2018-11-882993
10. Karbach S., Lagrange J., Wenzel P. Thromboinflammation and Vascular Dysfunction. Hamostaseologie, 2019, vol. 39 (2), pp. 180–187. doi: 10.1055/s-0038-1676130
11. Palankar R, Greinacher A. Challenging the concept of immunothrombosis. Blood. 2019; 133(6):508-509. doi: 10.1182/blood2018-11-886267
12. Matucci-Cerinic M., Bruni C., Allanore Y., Clementi M., Dagna L., Damjanov N.S., de Paulis A., Denton C.P., Distler O., Fox D., Furst D.E., Khanna D., Krieg T., Kuwana M., Lee E.B., Li M., Pillai S., Wang Y., Zeng X., Taliani G. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis, 2020, vol. 79, pp. 724–727. DOI: 10.1136/annrheumdis-2020-217407